ABSTRACT Human infection with highly pathogenic avian influenza A viruses causes severe disease and fatalities. We previously identified a potent and broadly neutralizing antibody (bnAb), 13D4, against the H5N1 virus. Here, we report the cocrystal structure of 13D4 in complex with the hemagglutinin (HA) of A/Vietnam/ 1194/2004 (H5N1). We show that heavy-chain complementarity-determining region 3 (HCDR3) of 13D4 confers broad yet specific neutralization against H5N1, undergoing conformational rearrangement to bind to the receptor binding site (RBS). Further, we show that mutating four critical residues within the RBS-Trp153, Lys156, Lys193, and Leu194 -disrupts the binding between 13D4 and HA. Viruses bearing Asn193 instead of Lys/Arg can evade 13D4 neutralization, indicating that Lys193 polymorphism might be, at least in part, involved in the antigenicity of recent H5 genotypes (such as H5N6 and H5N8) as distinguished from H5N1. BnAb 13D4 may offers a template for therapeutic RBS inhibitor design and serve as an indicator of antigenic change for current H5 viruses. IMPORTANCE Infection by highly pathogenic avian influenza A virus remains a threat to public health. Our broadly neutralizing antibody, 13D4, is capable of neutralizing all representative H5N1 viruses and protecting mice against lethal challenge. Structural analysis revealed that 13D4 uses heavy-chain complementarity-determining region 3 (HCDR3) to fit the receptor binding site (RBS) via conformational rearrangement. Four conserved residues within the RBS are critical for the broad potency of 13D4. Importantly, polymorphism of Lys193 on the RBS may be associated with the antigenicity shift from H5N1 to other newly emerging viruses, such as H5N6 and H5N8. Our findings may pave the way for highly pathogenic avian influenza virus vaccine development and therapeutic RBS inhibitor design.
(10-12). Vaccines and therapeutics (13) (14) (15) (16) (17) that target the H5 subtype are thus urgently needed.
Hemagglutinin (HA) is one of the three membrane proteins on the surface of the influenza virus responsible for receptor recognition and virus entry. The head of the HA1 subunit harbors the major targeting sites of neutralizing antibodies to influenza virus (18, 19) . The HA2 subunit is an ␣-helix-rich "stem" region of the HA trimer that functions to anchor the HA trimer onto the viral envelope membrane (20) . We and others have described several broadly neutralizing antibodies (bnAbs) that target either the HA1 receptor binding site (RBS) or the HA2 stem region of H5N1 virus (21) (22) (23) . Structure analysis of HA complexes with antibodies has provided insight into the molecular basis for the properties of broadly neutralizing antibodies (24) (25) (26) (27) . Canonically, heavy-chain complementarity-determining region 3 (HCDR3) is most diverse in both length and amino acid sequence and is often the major determinant of the specificity of antibody-antigen recognition (28) (29) (30) . Upon binding to the RBS of influenza virus, bnAbs commonly use their HCDR loops to plug or fit the structural contour of the narrow pocket of the RBS by mimicking binding of the sialoglycan receptor (31, 32) . For example, the monoclonal antibody (MAb) CH65 extends the HCDR3 loop into the pocket and is thus capable of neutralizing 30 representative seasonal H1 viruses (33, 34) . In contrast, MAb C05 has an extraordinarily long HCDR3 loop that covers the entire RBS (58) , facilitating broad neutralization against H1, H2, H3, H9, and H12. Other MAbs have different actions: HCDR3 of S139/1 recognizes various RBSs of H1, H2, H3, and H13 (59) , whereas HCDR3 of F045-092 recapitulates the binding of the ␣-2,6 of the sialoglycan receptor, neutralizing almost all H3 viruses (60) . Recently, a human antibody, AVFluIgG03, was identified, with broad-spectrum activity against most H5N1 clades, except for clades 1, 4, and 8, which were isolated between 1997 and 2008 (22, 35) . The crystal structure of AVFluIgG03 in complex with A/Anhui/1/2005 HA highlights its significant neutralization breadth through HCDR3 targeting of the RBS.
Previously, we generated a panel of 14 anti-H5N1 broadly neutralizing MAbs, among which MAb 13D4 presented as the most efficacious in terms of its therapeutic potential, with the widest neutralization capacity. Here, we solve and characterize the crystal structures of the 13D4 Fab and its complex with the A/Vietnam/1194/2004 (VN1194) HA ectodomain. We show that HCDR3 of 13D4 targets the RBS of the HA head region (HAhr) by conformational rearrangement. Using structure-guided mutagenesis, we identify the key binding sites that are specifically conserved among the H5N1 isolates. Furthermore, we show that 13D4 can neutralize the most recent H5N1 strains. To our knowledge, 13D4 might represent one of the most broad-spectrum H5N1 neutralizing antibodies. Intriguingly, the antibody loses its neutralization activity against other H5N1 genetic derivatives, such as H5N6 and H5N8, which emerged in recent years, presumably under evolutionary pressure caused by massive application of poultry vaccine. We used structural comparisons among the HA crystal structures bearing polymorphisms in key 13D4 binding sites to identify the determinants of antigenic shift from H5N1 to other H5 genotypes. Collectively, our findings offer molecular insight into the broad yet specific antibody-mediated neutralization of H5N1, which might be partially related to the antigenic shift from H5N1 to other genotypes, and provide a strategy for the design and optimization of antiviral therapeutics and broad-spectrum vaccines against H5N1 infection.
RESULTS
Overall structure of 13D4:HAhr. To elucidate how the 13D4 MAb neutralizes all of the representative H5N1 isolates, we solved the crystal structures of the 13D4 Fab alone and in complex with the VN1194 HA head region (13D4:HAhr) to 2.30-Å and 2.33-Å resolution, respectively, and refined to R work /R free values of 20.5% and 24.3%, and 17.3% and 21.9%, respectively (Table 1) . Four 13D4 Fab molecules are found in the asymmetric unit and display consistent conformation of the CDR loops, albeit HCDR3 is involved in crystal packing (Fig. 1A) . For crystallization of the immune complex, HA was generated in baculovirus-infected insect cells, as described by Stevens et al. (36) . One trimeric HA can bind three 13D4 Fabs in solution, as shown in the continuous molar mass distribution [c(M)] profiles of the analytical ultracentrifugation (AUC) assay (Fig. 1B) and two-dimensional (2D) average figures of cryo-electron microscopy (EM) imaging (Fig. 1C) . Purified HA0 was digested with thrombin and trypsin and mixed with the 13D4 Fab for crystallization ( Fig. 1D and E) . However, in the asymmetric unit of the HA:13D4 Fab complex, one 13D4 Fab binds with only the head region of HA1 (amino acids [aa] 47 to 309; H3 numbering), denoted HAhr (Fig. 1F , G, and I). HA might have degraded due to the length (ϳ3 months) of the crystallization process. However, we found that the structure of the HA1 head region is congruent with the corresponding moiety of the full-length Viet04 HA trimer structure (Protein Data Bank [PDB] accession no. 2IBX) (superimposition with a root mean square deviation [RMSD] of 0.37 Å for all HA1 C-␣ atoms) (Fig. 1G) . The glycan chains linked to Asn158 and Asn169 in our HA1 structure are well resolved in the electron density map ( Fig. 1F and H) and superimpose with HA1 of trimeric HA (Fig. 1F) . Overall, the 13D4 interaction interface in HA1 is located on the RBS; this is consistent with our previous result for the escape mutation 
e R free is calculated using the same equation as for R factor , but 5.0% of the reflections were chosen randomly and omitted from the refinement. on 13D4 neutralization. 13D4 Fab in the complex has a well-defined electron density map and shares similar overall structure with the free 13D4 Fab (RMSD, 0.85 Å for all of the C-␣ atoms), except for a significant change in HCDR3 (Fig. 1A) .
Interactions between HA1 and 13D4 Fab. 13D4 Fab binds to the membrane-distal region of the globular head of HA at nearly 45°to the 3-fold axis of the HA trimer (Fig.  1F) . The HAhr-13D4 interaction buries 857 Å 2 of surface area on HA1, as calculated by PISA (37) ( Table 2 ). The heavy chain mediates most of the HAhr-13D4 contacts (75.6% of the total buried surface area of HA1, i.e., 648 Å 2 out of 857 Å 2 ). All three loops of the CDR on the 13D4 heavy chain (HCDR) bind the RBS, which is framed by four structural elements: the 130 loop, the 150 loop, the 190 helix, and the 220 loop ( Fig. 2A) . We found that HCDR1 binds to the ridge between the 130 loop and the 150 loop, HCDR2 binds to the 150 loop, and HCDR3 binds deeply into the negatively charged RBS core region. In contrast, the light-chain CDR (LCDR) loops mostly make contact with the residues outside the RBS, i.e., LCDR1 to -3 bind to the regions near the 190 helix and the 220 loop ( Fig. 2A to C) . Together, these CDR recognitions define a conformational epitope comprising four stretches of amino acids: Glu131 to Ser137, Trp153 to Ser159, Asn186 to Leu194, and Lys222 to Gln226. These amino acid stretches are highly conserved (83%) among all H5 isolates (n ϭ 5,693; data collected before 2016 from the NCBI Influenza Virus Resource) ( Fig. 2B and Table 3 ). Our observations are also consistent with our previous data on the neutralization breadth and potency of MAb 13D4. In this complex structure, extensive interactions are established, with 16 hydrogenbonding contacts and 6 salt-bridging linkages (Table 2) formed between the side chains of the epitope residues (Fig. 2D ) and the residues of 13D4 Fab (Fig. 2E) .
Structure-based mutational analysis of the 13D4 neutralization sites. In the HAhr:13D4 complex structure, 16 HA residues at the interface interact with the 13D4 Fab through their side chains (Table 2 ). To identify the residues critical for 13D4 binding, alanine-scanning mutagenesis was carried out on all 16 amino acids. All of the unprocessed HA mutants were detected in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ( Fig. 3A ) and resolved as trimers in solution, similar to wild-type (WT) HA (Fig. 3B ). We used 50% effective concentration (EC 50 ) (enzyme-linked immunosorbent assay [ELISA]) and affinity (surface plasma resonance [SPR]) measurements to confirm the importance of each mutation. Notably, 4 mutations (W153A, K156A, K193A, and L194A) dramatically decreased the binding of 13D4 with HA, with the EC 50 more than 20 times higher for these mutants than for WT HA ( Fig. 2F and G and 3C and D). The association/disassociation SPR responses of the four mutants to MAb 13D4 were undetectable. The other mutants showed affinities similar to that of WT HA, and two mutants (L133aA and S137A) showed significantly enhanced binding affinities to 13D4, with affinity constants (K D ) of ϳ53 nM to 5 to 8 nM (Fig. 3D) .
The functions of these four strategic residues are structural: Trp153 and Leu194 simultaneously interact with Val100 H , where the superscript H denotes heavy chain, making hydrophobic interactions and van der Waals attractions ( Leu194, 95.5%) among all H5 isolates, and the RBS localization ( Fig. 2B and Table 3 ) determines the broad neutralization specificity of the 13D4 epitope. These results are also consistent with our previous 13D4 neutralization experiment on virus escape, where we replaced Lys156 and Lys193 with Glu and Met, respectively. In addition, in the present study, we found alanine replacement of the other residues, such as Asn158, Asn186, Asp187, Lys222, and Gln226, could also perturb 13D4 binding to HA to some extent, with 5-fold lower affinity with respect to WT HA (Fig. 3D) . These residues, which line the outside the RBS (Fig. 2B ), might assist in antibody binding but do not appear to be critical for binding. 13D4 HCDR3 adaptive fitting to the RBS. Similar to other reported RBS-directed bnAbs, the HCDR3 loop of 13D4 binds deeply within the RBS groove. Notably, structural superimposition of HA-bound and unbound 13D4 Fabs packing in the crystals revealed substantial conformational changes at the HCDR3 loop (Fig. 1A) . Amino acids 93 to 101 of the HCDR3 loop of the free Fab would clash with the 220 loop of receptor binding domain (RBD) if 13D4 underwent direct binding to HA (Fig. 4A and B) . To avoid this collision, a subloop, aa 95 to 101, swings from the 220 loop toward the 190 helix at about 33.6°, with Arg94 H and Ala99 H acting as mechanical fulcrums ( Fig. 4A ; see Movie S1 in the supplemental material). There, the C-␣ atoms of Val100 H and Glu100a H move 8.3 Å and 7.6 Å, respectively, away to create hydrogen bonding and hydrophobic interactions with Ser136, Ser137, Trp153, Leu194, and Ile155 (Fig. 4B) . The conformational fitting over the RBS may determine the broad yet specific nature of MAb 13D4, and this mode of binding is rarely observed in other bnAb-mediated binding. Indeed, in the literature, the HCDR3 loop of MAb H5.3 has been reported to rotate 90°in situ between its unliganded and liganded positions (38) , which is distinct to the conformational change of MAb 13D4.
Minor conformational changes were also observed in the RBS during HCDR3 binding; most notably, the side chain of Lys193 rotates to accommodate the gap created by the benzpyrole rings of Trp100d H and Trp33 H and donates a hydrogen bond to Glu50 H . There is also subtle perturbation to the side chain of Ile155, which constitutes a hydrophobic cavity, together with Trp153 and Leu194, for the binding of Val100 H of HCDR3 (Fig. 4C) . Compared to the free Fab structure, the fitted conformation of the HCDR3 loop against the RBS might be induced energetically by the spatial restriction of the RBS structural contour ( Fig. 4D ; see Movie S1 in the supplemental material). These interactive conformational changes manifest an induced fit during HA-13D4 binding, and, given that W153A and L194A mutations abrogate this HA-13D4 binding, it is likely that these residues are critical for the HA-13D4 interaction ( Fig. 1F and 2A) . Comparison with receptor analogue and other H5 head region antibodies. We next sought to compare the 13D4:HAhr structure with the structure of an avian receptor analogue (LSTa [3=-sialyl-N-acetyllactosamine]) bound to HA (PDB accession no. 3ZP0) (39) and with other immune complexes that contain H5 head region antibodies. Overall, the tip residues E100a H and V100 H of the 13D4 HCDR3 loop recapitulate the receptor analogue binding scenario (Fig. 5A to D) .
There are two major interactions between LSTa and the RBS, one through hydrogen bonding and one through hydrophobic interactions. In the first, triple hydrogen bonding occurs between the sialic acid carboxylate and Ser136 and Ser137 inside the RBS (Fig. 5A ). The carboxylate of E100a H creates four hydrogen-bonding connections with Ser16 and Ser137, and the hydroxyl group of the side chain of Ser137 receives one more hydrogen bond than LSTa (Fig. 5B) . Although other receptor-mimetic antibodies against H1 and H3 show similar hydrogen-bonding scenarios (PDB accession no. 4XNM, 3SM5, 4M5Z, 2VIR, 1KEN, and 4O58) (38, 40, 41) , 13D4 uses Glu instead of Asp for its hydrogen-bonding network (Fig. 5A and F) . This hydrogen-bonding modality differs from those of other H5 RBS-directed MAbs: H5.3 exclusively uses the main chain of Asp for H bonding, whereas AVFluIgG03 does not form hydrogen bonds via its Asp residue (Fig. 5E) . Thus, the use of Glu to recapitulate hydrogen bonding instead of Asp in 13D4 is unique (Fig. 5F ). No similar hydrogen bonding between 13D4 Fab and the RBS was observed, as the LSTa acetamide accepts a hydrogen bond from the main chain of Val135 (Fig. 5A and B) . For the second major interaction, the sialic acid of LSTa binds to a hydrophobic region created by the highly conserved Trp153, Ile155, and Leu194 in almost all H5 isolates (Table 3) . The tip residue, Val100 H , of the 13D4 HCDR3 loop binds to this region via its hydrophobic side chain, which is also observed in many other antibodies, such as CH65 and 2G1 (33, 42) .
All of the reported structures for HA-H5 bnAbs show targeting of the HA head region, but they can be further classified into two groups: non-RBS-directed binding (MAbs 65C6, 100F4, FLD194, and H5M9 [43, 44] ), with footprints shifted toward the distal membrane and twisting counterclockwise about 60°along the HA 3-fold axis with respect to the RBS (Fig. 5G, H, and J) , versus RBS-directed binding, where 13D4, AVFLuIG03, and H5.3 all share similar binding orientations against HA and define an overlapping region (Fig. 5G to I) . However, the key residues mediating binding of 13D4, AVFLuIG03, and H5.3 to HA are different, and this may account for the differences noted in the breadths of neutralization. 13D4 corresponds to sites more conserved than those of the other two MAbs (Fig. 5I and Table 4) .
A key 13D4 binding site associated with antigenicity shift from H5N1 to other H5 viruses. In our previous study, we showed that MAb 13D4 conferred broad neutralization against all representative H5 isolates identified between the years 1997 and 2009 and was verified as a potential therapeutic candidate for curing H5-infected animals from lethal infection following H5 virus challenge. To confirm the neutralization breadth since our previous study, we tested the emergent H5 subtype viruses isolated from 2012 to 2014 using HA inhibition (Fig. 6A) . The data showed that our 13D4 MAb can inhibit hemagglutination of H5N1, but not H5N6 and H5N8, two viral subtypes that first emerged in 2013 and 2006, respectively (Fig. 6A, table) . We then analyzed the antigenic shifts of the emergent H5N6 and H5N8 from their ancestral H5N1 (62) using escape neutralization of 13D4. Sequence alignment of the H5 HAs revealed that only 2 residues, D187N and K/R193N, of the 15 13D4 epitope residues are mutated between H5N1 and H5N6/H5N8, both located on the 190 loop (Fig. 6A) . In our structure and mutagenesis analysis, Asp187 was not involved in 13D4 binding, whereas the side chain of Lys193 was shown to play a strategic role in the interaction between 13D4 and HA (Fig. 2F, G, and J) . Moreover, 13D4 maintains strong neutralization against H5N1 viruses that retain Arg193 in HA, such as HK/5923/2012 and Zhejiang/98/2014 isolates, and also those viruses bearing the Lys193 residue (Fig. 6A) . Superimposition of the HA structures with either Lys193 or Arg193 showed similar interaction with Trp33 H , Glu50 H , and Trp100d H of 13D4 (Fig. 6B) . However, Asn193 of H5N6/H5N8 has a shorter side chain than Lys/Arg and thus abrogates 13D4 recognition, possibly because it fails to establish the critical interaction for 13D4 binding (Fig. 6C) . Polymorphic analysis of residue 193 among 5,693 H5 isolates revealed high conservation of the Lys/Arg residue at this position, with 88.4% identity (Table 5) . Lys/Arg193 is completely conserved in all 13D4-reactive H5 isolates (Table 3) .
DISCUSSION
Although H5 subtype influenza viruses still exclusively circulate in avian hosts, cross-species infection in sporadic human cases led to severe disease, with a Ͼ50% mortality rate. No effective antiviral is available for the treatment of human infection with H5N1 or other highly pathogenic H5 subtype viruses. Like other influenza viruses, H5 subtype virus evolves rapidly in the field. Development of broadly neutralizing antibodies has been considered one of the therapeutic means to respond to the potential threat of highly pathogenic avian influenza viruses. We previously characterized an H5-specific broadly neutralizing antibody, 13D4, and showed potent therapeutic activity against H5N1 infection in mice (21) . Here, we report the structure and function of this potent neutralizing antibody against H5N1 isolates. We show that HCDR3 adaptively fits into the shallow groove of the HA RBS and highlight the key residues involved in this binding.
Comparing sequence conservation and genetic variation, there are three highly conserved regions on HA that are associated with the bnAbs, including the RBD, the L133a, S136,  S137, W153A,  I155A, K156, N158,  S159, N186, D187,  E190, K193, L194,  K222, Q226 E131, S133, S133a, V135, S136, S137 , T144, P145,  W153, I155, K156, K157,  N158, N159, K193, L194,  K222, Q226   Y98, L133a, V135,  S136, S137, Q142,  G143, K144, S145,  W153, I155, K156,  N158, S159, E190,  K193, L194, G225,  Q226   I121, Q122, I123, P125,  S125b, D129, P162, T163,  K165, R166, S167, Y168,  N169, T171, N172, N244,  E246 D77, E78, I80, N81, H117, E119, K120, I121, Q122, K125a, Y141, Q142, R149, T171, N172, Q173, E174, Y256, K259, V260a, K261  I80, N81, K120, I121,  Q122, I123, I124,  S125b, S126, S128,  Y141, Q142, K144,  N150, R166, S167,  Y168, N169, T171,  E255, Y256, K259   D53, D55, G55a,  V56, K57, R62,  E78, N81, P83,  E83a, H117,  E119, E273,  Y274, stem region, and the vestigial esterase region (45) . Most isolated bnAbs target the RBD, such as 5J8, 1F1 (63) , and CH65, with single-subtype-specific breadth, and C05, S139/1, and F045-092, with cross-subtype activity. The globular head domain bears the conserved RBS, which mediates host specificity and is responsible for the antigenic shift and antigenic drift in the major antigen determinants, which leads to escape from viral neutralization. Notably, bnAbs usually demonstrate receptor mimicry through various binding strategies using the HCDR3 loop. In the case of the H5 subtype, two known bnAbs, AVFluIgG03 and H5.3, are RBS-directed antibodies, and HCDR3 inserts directly into the binding groove. These RBS-directed antibodies neutralize all clades of H5 (except 1, 4, and 8), as well as VN/1203 and two H5 rdt variants only, respectively ( Fig.  5I and J) . Our 13D4 can neutralize all major H5N1 clades isolated between 1997 and 2014. Structure-guided mutagenesis on 13D4 binding sites has identified four highly conserved amino acids in its targets, which may account for the wide breadth of coverage. 13D4 mimics sialic acid-containing receptor binding, similar to other bnAbs, such as 5J8, CH65, and F045-092. However, we showed that it identifies a unique Val-Glu motif instead of the known Val-Asp to recapitulate the hydrogen-bonding network of receptor binding. Glu harbors a C atom side chain that is longer than that of Asp, which allows it to preferentially donate hydrogen bonds to Ser136 and Ser137 (Fig. 5E ). The structural mimicry of the receptor analogue might explain the broad neutralization achieved by 13D4, in concert with conservation of the key sites. Structural comparison of the unbound and bound 13D4 Fab highlights the significant conformational changes that occur in HCDR3 (Fig. 4A and B) , and this rearrangement simultaneously induces subtle side chain rotamer changes on Lys193 and Ile155 to accommodate its fitting (Fig. 4C) . Unlike changes invoked by other bnAbs, 13D4 HCDR3 in its original unbound state would bump into the 220 loop, with the other loops also contacting HA (Fig. 4B) . We reason that this physical obstruction would cause the HCDR3 loop to "flap away" from the 220 loop and then adaptively fit into the RBS groove. Eventually, the side chains of Ala99 H and W100d H would almost fill the space of the RBS rather than the receptor analogue. It is worth noting that fitting is further optimized when the side chain of Asp100c H inserts into the gap instead of extending outside the RBS (Fig. 4D) . Intriguingly, replacement of Ser136 or Ser137 with Ala does not decrease but exceptionally enhances the binding affinity of 13D4 for HA (Fig. 2G) , as shown in the smoothed dissociation curve of the SPR trace and the decreased dissociation rate (Fig. 3D) ; this indicates that the initial stage of conformational rearrangement might be related to the final stable binding conformation. We synthesized several oligopeptides according to the 13D4 HCDR3 sequence but found no activity against HA in SPR or isothermal titration calorimetry (ITC) (data not shown), implying that the HCDR3 loop alone is insufficient to undergo the proper conformational changes required for the action of the 13D4 antibody. Thus, a more rational strategy should be devised, such as the use of pharmacophore-based designs or sequential molecular-dynamic simulation (46) . Nevertheless, our structures of the two-state HCDR3 loops, the key conserved neutralization sites, and the conformational rearrangement will aid in the design of efficacious polypeptides or therapeutic drugs against the H5 subtype virus.
The threat of HPAI H5 subtype virus spread to humans is still present, given the recent emergence of new H5N1 variant subclades (2.3.4.4) (47, 48) and other reassortants, including H5N2, H5N3, H5N5, H5N6, and H5N8, in poultry in Asia, Europe, and North America. Human infections with the H5N6 strain have been observed (49) . The H5N6 virus has undergone more than 17 site mutations (50) in the HA1 primary sequence compared with the original H5N1 in infected humans (Fig. 6A) . Most of these mutated sites do not reside in the 13D4 binding sites, with only position 193 related to 13D4 neutralization activity (Fig. 6A) . Although HA with Lys193 or Arg193 is reactive to [51, 52] and site B for H3 [53, 54] ) on the HA RBD; however, it is quite distinct in polymorphism among H1, H3, and H5 subtypes, i.e., the amino acid types with the highest frequencies are Ser (ϳ78%) and Thr (ϳ12%) for H1; Phe (ϳ56.5%), Asn (ϳ17%), and Ser (ϳ22%) for H3; and Lys (ϳ50%) and Arg (38.4%) for H5. Other key residues involved in 13D4 interaction are also attributed to major antigenic sites of other genotypes, i.e., residues 156 and 194 residing in the Sa/Sb site for H1 or site B for H3, whereas residue 153 is located in the RBS of all genotypes. The structural basis characterized from bnAb 13D4 and the HA complex may provide a molecular basis for vaccine strain selection and design of therapeutic reagents for pan-H5 protection.
MATERIALS AND METHODS
Cloning, expression, and purification of HA. The HA gene of A/Vietnam/1194/2004 (Viet04; accession no. EF541402), encoding HA1 aa 11 to 329 (H3 sequence numbering) and HA2 aa 1 to 174, was cloned into the baculovirus transfer vector pAcGP67B (BD Biosciences) using the Gibson assembly cloning method for baculovirus preparation. The construct contains an N-terminal gp67 secretion signal peptide, a thrombin cleavage site, a T4 fibritin "foldon" domain to assist in trimerization of the product, and a C-terminal 6-His tag for purification, as previously described. Site-directed HA mutants were constructed using a Mut Express II fast mutagenesis kit V2 (Vazyme). For the expression of recombinant HA proteins, Hi5 suspension cells (Invitrogen) were infected with recombinant baculovirus at a multiplicity of infection (MOI) of 5 to 8 at 28°C for 72 h. The supernatant was then dialyzed against phosphate-buffered saline (PBS), pH 7.4, and purified with Ni-nitrilotriacetic acid (NTA) resin (GE Healthcare) by the elution of 250 mM imidazole. HA proteins for crystallization were treated with thrombin to remove the C-terminal fusion elements and further digested with 200 mU/mg HA TPCK (tosylsulfonyl phenylalanyl chloromethyl ketone)-treated trypsin (Sigma-Aldrich) to cleave HA0 into HA1 and HA2. Trypsin was quenched with 2 mM phenylmethylsulfonyl fluoride (PMSF) (Beyotime). The purified HA proteins were mixed with loading buffer (50 mM Tris, pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 0.01% bromophenol blue, 8% glycerol), boiled for 10 min, and subjected to SDS-PAGE.
Purification, crystallization, and structure determination. The 13D4 Fab was prepared by papain digestion of MAb 13D4 (64) and purified with DEAE-5PW (Tosoh Bioscience, Tokyo, Japan), as described previously (55) . HA was mixed with 13D4 Fab in a molar ratio of 1:3.2 and incubated at 37°C for 2 h. The immune complex was purified by gel filtration on a Superdex 200 column (GE Healthcare) in 10 mM Tris, pH 8.0, with 50 mM NaCl. The free 13D4 Fab and its complex with HA were concentrated to ϳ20 and ϳ8.5 mg/ml, respectively, for crystallization. The crystallization was implemented by sitting-drop vapor diffusion in the screening stage and hanging drop in microseeding optimization at 20°C. Crystals of 13D4 Fab were grown in 12.5% (wt/vol) polyethylene glycol (PEG) 3350, 150 mM potassium acetate, whereas the complex crystals were grown in 0.1 M Bis-Tris-propane, pH 6.5, 0.2 M sodium acetate, and 18% (wt/vol) PEG 3350. Crystal growth of the immune complex took about 3 months for final data collection. Crystals were cryoprotected in reservoir solution supplemented with 30% glycerol at 100 K. Diffraction data were collected at Shanghai Synchrotron Radiation Facility (SSRF) beamline BL17U using a Quantum315r charge-coupled-device (CCD) area detector. Data sets were processed using the HKL-2000 program package (HKL Research, Inc.). According to the results from multiple input trials with proposed molecular mass, only a protein of 78 kDa (corresponding to one Fab [47 kDa] plus one HA head region [31 kDa], spanning aa 47 to 309 of HA1 in the final model) in one asymmetry unit gives a Matthews coefficient of 2.58 Å 3 /Da, related to 52.3% solvent content, with probabilities of 1.00 both for high resolution and overall, which indicates a protein(s) of about 78 kDa is harbored in the crystal (56) . Then, we used this permutated complex of partial HA and one Fab for phase searching in molecular replacement (MR), which was implemented with the PHASER suite (65), using Phenix to find the initial phases. The search models for the light chain and heavy chain of 13D4 Fab were PDB accession no. 3CLE and 4KI5, respectively. The final 13D4 Fab model and head region of HA (PDB accession no. 2IBX) served for the MR search. The resulting models were manually built in COOT (66) , refined with PHENIX (67), and analyzed with MolProbity (57) . In brief, one round of rigid-body refinement was performed after MR. The refined models were manually modified in COOT; coordinates and individual B factors were refined in reciprocal space. Translation/libration/screw (TLS) refinement was performed in the later stages with autosearched TLS groups in PHENIX, which are listed in the REMARK 3 sections in the deposited PDB files. The data collection and structure refinement statistics are summarized in Table 1 .
